Evolus, Inc. Common Stock (EOLS) Financials

EOLS Assets vs Liabilities

DateAssetsLiabilities
2024-03-31 226.2 million 207.7 million
2023-12-31 189.0 million 209.7 million
2023-09-30 168.0 million 187.3 million
2023-06-30 169.0 million 175.9 million

EOLS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2024-03-31 -11.4 million 5.1 million
2023-12-31 452000 4.4 million
2023-09-30 -35.4 million 4.6 million
2023-06-30 -13.5 million 4.2 million

EOLS Net Income

No data available :(

EOLS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2024-03-31 97.0 million - 6.0 million
2023-12-31 62.8 million - 6.2 million
2023-09-30 38.7 million - 6.3 million
2023-06-30 41.7 million - 2.0 million

EOLS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2024-03-31 58.8 million
2023-12-31 57.2 million
2023-09-30 57.0 million
2023-06-30 56.9 million

EOLS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2024-03-31 797000 2.1 million 45.1 million -
2023-12-31 361000 2.4 million 35.6 million 7.5 million
2023-09-30 539000 1.6 million 43.3 million -
2023-06-30 216000 1.2 million 42.9 million -

EOLS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2024-03-31 59.3 million 19.5 million
2023-12-31 61.0 million 20.6 million
2023-09-30 49.3 million 15.4 million
2023-06-30 49.3 million 14.7 million

EOLS

Price: $13.59

52 week price:
7.07
15.43

Earnings Per Share: -1.08 USD

P/E Ratio: -12.23

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Volume: 16622

Market Capitalization: 798.3 million

Links: